生物制剂初治炎症性肠病患者对维多珠单抗治疗的快速应答
该研究对维多珠单抗治疗溃疡性结肠炎(UC,N=374)和克罗恩病(CD,N=784)的3期随机对照试验数据进行事后分析,评估未用过和用过肿瘤坏死因子(TNF)拮抗剂患者的早期应答。结果显示,UC患者(总体及TNF拮抗剂初治)在第2、4、6周达到预设复合症状评分的比例显著高于安慰剂组;CD初治患者在第2、4周显著高于安慰剂组。结论认为维多珠单抗最早在第2周即显著改善患者报告症状,并持续至第6周,尤其作为一线生物制剂时。
要点
- UC患者用维多珠单抗第2周达复合评分者19.1%(总体)、22.3%(TNF拮抗剂初治),安慰剂组分别为10%、6.6%。
- CD初治患者用维多珠单抗第2周达复合评分者15.0%,安慰剂组7.9%;第4周分别为23.8%和10.3%。
- 维多珠单抗作为一线生物制剂时早期症状改善更明显,持续至第6周。
核心结论
- 事后分析显示,维多珠单抗最早在治疗第2周即显著改善UC和CD患者报告的症状,并持续至前6周,尤其作为一线生物制剂时。
研究设计与样本
- 对维多珠单抗对比安慰剂的3期随机对照试验数据进行事后分析,纳入成人UC患者374例和CD患者784例。
- 收集治疗第2、4、6周的患者报告症状(UC为直肠出血和排便频率,CD为腹痛和稀便频率),报告相对基线的平均百分比评分变化及达到预设评分的患者比例。
- 采用多变量逻辑回归分析识别与第2周早期应答相关的因素。
主要发现
- UC患者(总体或TNF拮抗剂初治)中,维多珠单抗组在第2、4、6周达到预设复合症状评分的比例显著高于安慰剂组。
- CD初治患者中,维多珠单抗组在第2、4周达到预设评分的比例显著高于安慰剂组。
- UC用维多珠单抗者第2周达直肠出血评分0且排便频率≤1的复合评分比例为19.1%(总体)和22.3%(TNF拮抗剂初治),安慰剂组分别为10%(总体)和6.6%(TNF拮抗剂初治)。
- CD初治患者用维多珠单抗者第2周达每日平均腹痛评分≤1且稀便频率≤3的比例为15.0%,安慰剂组为7.9%;第4周分别为23.8%和10.3%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Vedolizumab, a humanized monoclonal antibody against α4β7 integrin, is used to treat adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). We investigated the time course of clinical response to vedolizumab in patients who were and were not previously treated with tumor necrosis factor (TNF) antagonists. METHODS: We performed a post-hoc analysis of data from phase 3, randomized, controlled trials of vedolizumab vs placebo in adult patients with UC (N = 374) or CD (N = 784). We collected data on patient-reported symptoms (rectal bleeding and stool frequency for patients with UC, abdominal pain and loose stool frequency for patients with CD) reported at weeks 2, 4, and 6 of treatment. We reported mean percentage score changes from baseline and proportions of patients who achieved predefined scores. We performed multivariate logistic regression analysis to identify factors associated with an early response (at week 2). RESULTS: In patients with UC (overall or naive to TNF antagonist therapy), a significantly greater percentage of patients given vedolizumab achieved the predefined composite symptom score at weeks 2, 4, and 6 compared to those given placebo. In patients with CD who were naive to TNF antagonists, a significantly greater percentage of patients given vedolizumab achieved the predefined score at weeks 2 and 4 compared to those given placebo. Among patients with UC given vedolizumab, 19.1% (overall) and 22.3% (TNF antagonist naive) achieved a composite score of rectal bleeding of 0 and stool frequency ≤1 at week 2 compared to 10% (overall) and 6.6% (TNF antagonist naive) of those receiving placebo. Among TNF antagonist-naive patients with CD, 15.0% of those given vedolizumab achieved an average daily composite score of abdominal pain ≤1 and loose stool frequency ≤3 at week 2 (compared to 7.9% given placebo), and 23.8% of those given vedolizumab achieved these by week 4 (compared to 10.3% given placebo). CONCLUSIONS: In a post-hoc analysis of data from phase 3 clinical trials, vedolizumab significantly improved patient-reported symptoms of UC and CD as early as week 2 of treatment, continuing through the first 6 weeks-especially when given as first-line biologic therapy. ClinicalTrials.gov no: NCT00783718, NCT00783692, NCT01224171.
引用
- Feagan BG, Lasch K, Lissoos T, et al. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018. PMID: 29857145. doi:10.1016/j.cgh.2018.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。